JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

Trial Details

NCT ID

NCT06514768

Phase

EARLY_PHASE1

Sponsor

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Status

RECRUITING

Cancer Type

Acute Lymphoblastic (ALL) Leukemia

Interventions

• JY231

Locations (sample)

• Kunming, Yunnan, China|25.03889,102.71833

Key Eligibility Criteria

• up to 75 years (Child, Adult) , either sex；
• Bone marrow cell morphology examination showed the proportion of primitive and immature lymphocytes in the bone marrow is \>5%, or the bone marrow …
• Flow cytometry or histology confirmed positive expression of cluster of differentiation 19 (CD19);
• According to the researcher's assessment, the expected survival period is greater than 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.